monoclonal antibody 3F8
Sponsors
Memorial Sloan Kettering Cancer Center
Conditions
Neuroblastoma
Phase 1
Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma
CompletedNCT00037011
Start: 2001-11-30Updated: 2013-01-18
Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma
CompletedNCT00450307
Start: 2005-06-30End: 2013-04-30Updated: 2013-10-16
Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma
CompletedNCT00492167
Start: 2005-09-09End: 2022-03-04Updated: 2022-03-07
Phase 2
Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma
CompletedNCT00004110
Start: 1999-08-31Updated: 2013-10-31
Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma
CompletedNCT00002560
Start: 1994-02-28End: 2005-04-30Target: 40Updated: 2013-06-28
Multiple Therapies in Treating Patients With Advanced Neuroblastoma
CompletedNCT00040872
Start: 2000-06-30End: 2007-01-31Updated: 2013-03-07
Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment
CompletedNCT00089258
Start: 2004-07-31Target: 74Updated: 2013-01-17
Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma
CompletedNCT00002634
Start: 1995-02-28End: 2004-09-30Target: 45Updated: 2013-07-03
Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission
CompletedNCT00002458
Start: 1987-11-30End: 2001-09-30Updated: 2013-06-05